Literature DB >> 28234803

Clinical significance of 11-oxygenated androgens.

Adina F Turcu1, Richard J Auchus.   

Abstract

PURPOSE OF REVIEW: The adrenal gland is considered a source of weak androgens, such as dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androstenedione. Emerging evidence proposes a set of 11-oxygenated 19-carbon (11oxC19) adrenal-derived steroids as clinically important androgens. Such steroids include 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone, and 11-ketotestosterone. The present review will discuss the synthesis, androgenic activity, and clinical implications of the 11oxC19 steroids. RECENT
FINDINGS: The clinical relevance of the 11oxC19 steroids resides in two key characteristics: the synthesis of all 11oxC19 originates predominantly in the adrenal cortex, and 11-ketotestosterone and its 5α-reduced metabolite, 11-ketodihydrotestosterone are potent agonists of the human androgen receptor, similar to the classic androgens testosterone and dihydrotestosterone, respectively. Recent studies have demonstrated higher than normal circulating levels of 11oxC19 steroids in patients with 21-hydroxylase deficiency and in polycystic ovary syndrome. The 11oxC19 steroids are also thought to contribute to castration-resistant prostate cancer progression. In addition, the 11oxC19 steroids might have clinical implications in adrenarche and postmenopausal women.
SUMMARY: Future prospective studies are needed to establish the clinical utility of the 11oxC19 steroids for individualized patient care. Preliminary data suggest that these biomarkers hold promise to improve the evaluation and management of androgen excess disorders.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28234803      PMCID: PMC5819755          DOI: 10.1097/MED.0000000000000334

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  41 in total

1.  Perspectives in Polycystic Ovary Syndrome: From Hair to Eternity.

Authors:  Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 2.  Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Authors:  Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-29       Impact factor: 4.292

3.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Mahboubeh Papari-Zareei; Lori Watumull; Yan Daniel Zhao; Richard J Auchus; Nima Sharifi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

4.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.

Authors:  N Krone; A Braun; A A Roscher; D Knorr; H P Schwarz
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays.

Authors:  Omar N Akram; Christina Bursill; Reena Desai; Alison K Heather; Rymantas Kazlauskas; David J Handelsman; Gilles Lambert
Journal:  Anal Chem       Date:  2011-02-18       Impact factor: 6.986

6.  Transcriptome profiling reveals differentially expressed transcripts between the human adrenal zona fasciculata and zona reticularis.

Authors:  Juilee Rege; Yasuhiro Nakamura; Tao Wang; Todd D Merchen; Hironobu Sasano; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

7.  Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha.

Authors:  H Escobar-Morreale; F Pazos; N Potau; R García-Robles; J M Sancho; C Varela
Journal:  Fertil Steril       Date:  1994-09       Impact factor: 7.329

8.  Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.

Authors:  R Azziz; V Black; G A Hines; L M Fox; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

9.  Development of a novel cell based androgen screening model.

Authors:  Carmela Campana; Juilee Rege; Adina F Turcu; Vincenzo Pezzi; Celso E Gomez-Sanchez; Diane M Robins; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2015-11-12       Impact factor: 4.292

10.  Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.

Authors:  Christopher M Jones; Ashwini Mallappa; Nicole Reisch; Nikolaos Nikolaou; Nils Krone; Beverly A Hughes; Donna M O'Neil; Martin J Whitaker; Jeremy W Tomlinson; Karl-Heinz Storbeck; Deborah P Merke; Richard J Ross; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

View more
  22 in total

1.  Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells.

Authors:  Lindsey K Ly; Joe L Rowles; Hans Müller Paul; João M P Alves; Camdon Yemm; Patricia M Wolf; Saravanan Devendran; Matthew E Hudson; David J Morris; John W Erdman; Jason M Ridlon
Journal:  J Steroid Biochem Mol Biol       Date:  2019-12-20       Impact factor: 4.292

2.  Circulating 11-oxygenated androgens across species.

Authors:  Juilee Rege; Scott Garber; Alan J Conley; Ruth M Elsey; Adina F Turcu; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-04-05       Impact factor: 4.292

Review 3.  11-Keto-testosterone and other androgens of adrenal origin.

Authors:  L Stárka; M Dušková; J Vítků
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

4.  Association between dehydroepiandrosterone sulphate levels at 7 years old and bone mineral density at 10 years old: a prospective cohort study.

Authors:  Rita Santos-Silva; Manuel Fontoura; Milton Severo; Raquel Lucas; Ana Cristina Santos
Journal:  Eur J Pediatr       Date:  2022-03-16       Impact factor: 3.183

5.  Association of dehydroepiandrosterone sulfate, birth size, adiposity and cardiometabolic risk factors in 7-year-old children.

Authors:  Rita Santos-Silva; Manuel Fontoura; João T Guimarães; Henrique Barros; Ana Cristina Santos
Journal:  Pediatr Res       Date:  2021-08-20       Impact factor: 3.953

Review 6.  The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Authors:  Marià Alemany
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

7.  11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.

Authors:  Monique Barnard; Jonathan L Quanson; Elahe Mostaghel; Elzette Pretorius; Jacky L Snoep; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2018-06-21       Impact factor: 4.292

8.  The Unique Role of 11-Oxygenated C19 Steroids in Both Premature Adrenarche and Premature Pubarche.

Authors:  Brittany K Wise-Oringer; Anne Claire Burghard; Patrick O'Day; Abeer Hassoun; Aviva B Sopher; Ilene Fennoy; Kristen M Williams; Patricia M Vuguin; Renu Nandakumar; Donald J McMahon; Richard J Auchus; Sharon E Oberfield
Journal:  Horm Res Paediatr       Date:  2021-02-02       Impact factor: 2.852

9.  11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool.

Authors:  Lise Barnard; Lina Schiffer; Renate Louw du-Toit; Jennifer A Tamblyn; Shiuan Chen; Donita Africander; Wiebke Arlt; Paul A Foster; Karl-Heinz Storbeck
Journal:  Endocrinology       Date:  2021-03-01       Impact factor: 5.051

10.  Abiraterone acetate treatment lowers 11-oxygenated androgens.

Authors:  Connor Wright; Patrick O'Day; Mohammed Alyamani; Nima Sharifi; Richard J Auchus
Journal:  Eur J Endocrinol       Date:  2020-04       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.